Global Scientific Director
Mirum Pharmaceuticals
Global Scientific Director
Mirum Pharmaceuticals
ASBT inhibitors for rare liver diseases
MISSION
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We are passionate about advancing scientific discoveries to become important medicines for rare disease patients. We are collaborative, creative, and experienced professionals and we’re looking to augment our team with other individuals who embody our values: care, be real, get it done, and have fun, seriously.
POSITION SUMMARY
Reporting to the Global Medical Affairs Lead, this individual will be responsible for internal and external scientific and clinical research initiatives under the Medical Affairs umbrella, supporting HDV and PSC/PBC (liver portfolio). This individual will also help develop the strategy, tactics, KOL engagement plan and disease state awareness activities for the adult hepatology programs. They will also help manage compassionate use and expanded use programs for the HDV and PSC/PBC programs.
The individual is a member of R&D and will provide scientific, clinical, and strategic feedback across all appropriate cross-functional teams.
JOB FUNCTIONS/RESPONSIBILITIES
QUALIFICATIONS
Education/Experience:
Knowledge, Skills and Abilities:
#LI-REMOTE
Mirum Pharmaceuticals is committed to Equal Employment Opportunity (EEO) and to compliance with all Federal, State and Local laws that prohibit employment discrimination on the basis of race, age, national origin, ethnicity, religion, gender, gender identity, pregnancy, marital status, sexual orientation, citizenship, genetic disposition or characteristics, disability, veteran’s status or any other classification protected by applicable State/Federal/Local laws.
Mirum Pharmaceuticals provides reasonable accommodation for qualified individuals with disabilities and disabled veterans in job application procedures.
ASBT inhibitors for rare liver diseases
Mirum develops therapies for rare liver diseases, led by LIVMARLI (maralixibat), an oral ASBT inhibitor that reduces bile acid buildup and itching in Alagille syndrome and other cholestatic conditions. It is pursuing LIVMARLI for additional rare diseases such as PFIC and biliary atresia and developing volixibat for primary sclerosing cholangitis and primary biliary cholangitis. The company combines drug development with commercialization in the United States and other major markets, working with physicians, payers, and patient groups to improve access. Its goal is to bring effective therapies to patients with rare liver diseases and build a sustainable commercial presence in key markets.
Explore more opportunities at Mirum Pharmaceuticals